PD05-09 FLUORESCENT-DIHYDROTESTOSTERONE BASED INHIBITOR IMPAIRED PROSTATE CANCER CELL LINE GROWTH AND ANDROGEN RECEPTOR SIGNALING

Authors :: Danny Holbert
Vitaliy M. Sviripa
James L. Mohler
John J. Stocking
Michael V. Fiandalo
David S. Watt
Hans Minderman
Krystin Mantione
John Wilton
Kristopher Attwood
Yue Wu
Source :: Journal of Urology. 201
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.
Abstract: INTRODUCTION AND OBJECTIVES:Men with advanced prostate cancer (CaP) receive androgen deprivation therapy (ADT), which lowers circulating testosterone (T) levels, impairs androgen receptor (AR) acti...

Subjects :: business.industry
Urology
urologic and male genital diseases
medicine.disease
Androgen deprivation therapy
Androgen receptor
Prostate cancer
Prostate cancer cell line
Dihydrotestosterone
Cancer research
Medicine
business
Testosterone
medicine.drug

Tools